Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 269

1.

The outcomes of mycophenolate mofetil therapy combined with systemic corticosteroids in acute uveitis associated with Vogt-Koyanagi-Harada disease.

Abu El-Asrar AM, Hemachandran S, Al-Mezaine HS, Kangave D, Al-Muammar AM.

Acta Ophthalmol. 2012 Dec;90(8):e603-8. doi: 10.1111/j.1755-3768.2012.02498.x. Epub 2012 Sep 12.

2.
3.

Prognostic factors for clinical outcomes in patients with Vogt-Koyanagi-Harada disease treated with high-dose corticosteroids.

Abu El-Asrar AM, Al Tamimi M, Hemachandran S, Al-Mezaine HS, Al-Muammar A, Kangave D.

Acta Ophthalmol. 2013 Sep;91(6):e486-93. doi: 10.1111/aos.12127. Epub 2013 Apr 10.

4.

Indocyanine green angiography in Vogt-Koyanagi-Harada disease: angiographic signs and utility in patient follow-up.

Herbort CP, Mantovani A, Bouchenaki N.

Int Ophthalmol. 2007 Apr-Jun;27(2-3):173-82. Epub 2007 Apr 25.

PMID:
17457515
5.

The effect on choroidal changes of the route of systemic corticosteroids in acute Vogt-Koyanagi-Harada disease.

Park UC, Cho IH, Lee EK, Yu HG.

Graefes Arch Clin Exp Ophthalmol. 2017 Jun;255(6):1203-1211. doi: 10.1007/s00417-017-3654-5. Epub 2017 Apr 5.

PMID:
28382438
6.

Outcomes of Vogt-Koyanagi-Harada Disease: A Subanalysis From a Randomized Clinical Trial of Antimetabolite Therapies.

Shen E, Rathinam SR, Babu M, Kanakath A, Thundikandy R, Lee SM, Browne EN, Porco TC, Acharya NR.

Am J Ophthalmol. 2016 Aug;168:279-286. doi: 10.1016/j.ajo.2016.06.004. Epub 2016 Jun 10.

7.

The outcomes of indocyanine green angiography monitored immunotherapy in Vogt-Koyanagi-Harada disease.

Chee SP, Jap A.

Br J Ophthalmol. 2013 Feb;97(2):130-3. doi: 10.1136/bjophthalmol-2012-302538. Epub 2012 Dec 4.

PMID:
23212203
8.

Evaluation of the effect on outcomes of the route of administration of corticosteroids in acute Vogt-Koyanagi-Harada disease.

Read RW, Yu F, Accorinti M, Bodaghi B, Chee SP, Fardeau C, Goto H, Holland GN, Kawashima H, Kojima E, Lehoang P, Lemaitre C, Okada AA, Pivetti-Pezzi P, Secchi A, See RF, Tabbara KF, Usui M, Rao NA.

Am J Ophthalmol. 2006 Jul;142(1):119-24.

PMID:
16815259
9.

Clinical characteristics of Vogt-Koyanagi-Harada syndrome in Chinese patients.

Yang P, Ren Y, Li B, Fang W, Meng Q, Kijlstra A.

Ophthalmology. 2007 Mar;114(3):606-14. Epub 2006 Nov 21.

PMID:
17123618
10.

Clinical Outcomes of Patients with Vogt-Koyanagi-Harada Disease Over 12 Years at a Tertiary Center.

Arevalo JF, Lasave AF, Gupta V, Kozak I, Al Harbi MB, Al Rushood AA, Al Dhibi HA.

Ocul Immunol Inflamm. 2016 Oct;24(5):521-9. doi: 10.3109/09273948.2015.1025984. Epub 2015 Sep 23.

PMID:
26399962
11.

Indocyanine green angiography-guided management of Vogt-Koyanagi-Harada disease: differentiation between choroidal scars and active lesions.

Knecht PB, Mantovani A, Herbort CP.

Int Ophthalmol. 2013 Oct;33(5):571-7. doi: 10.1007/s10792-012-9692-4. Epub 2013 Jan 1.

PMID:
23277207
12.

Influence of early cerebrospinal fluid-guided diagnosis and early high-dose corticosteroid therapy on ocular outcomes of Vogt-Koyanagi-Harada disease.

Miyanaga M, Kawaguchi T, Shimizu K, Miyata K, Mochizuki M.

Int Ophthalmol. 2007 Apr-Jun;27(2-3):183-8. Epub 2007 May 3.

PMID:
17476572
13.

Posterior segment recurrences in Vogt-Koyanagi-Harada disease.

Sachdev N, Gupta V, Gupta A, Singh R.

Int Ophthalmol. 2008 Oct;28(5):339-45. Epub 2007 Sep 26.

PMID:
17898934
14.

Retinal functional changes measured by microperimetry after immunosuppressive therapy in patients with Vogt-Koyanagi-Harada disease.

Abu El-Asrar AM, Al-Mezaine HS, Hemachandran S, Hariz R, Kangave D.

Eur J Ophthalmol. 2012 May-Jun;22(3):368-75. doi: 10.5301/ejo.5000035.

PMID:
21928252
15.

Incidence and clinical features of recurrent Vogt-Koyanagi-Harada disease in Japanese individuals.

Iwahashi C, Okuno K, Hashida N, Nakai K, Ohguro N, Nishida K.

Jpn J Ophthalmol. 2015 May;59(3):157-63. doi: 10.1007/s10384-015-0377-1. Epub 2015 Mar 26.

PMID:
25808016
16.

Earlier immunomodulatory treatment is associated with better visual outcomes in a subset of patients with Vogt-Koyanagi-Harada disease.

Urzua CA, Velasquez V, Sabat P, Berger O, Ramirez S, Goecke A, Vásquez DH, Gatica H, Guerrero J.

Acta Ophthalmol. 2015 Sep;93(6):e475-80. doi: 10.1111/aos.12648. Epub 2015 Jan 7.

17.

Choroidal observations in Vogt-Koyanagi-Harada disease using high-penetration optical coherence tomography.

Nakai K, Gomi F, Ikuno Y, Yasuno Y, Nouchi T, Ohguro N, Nishida K.

Graefes Arch Clin Exp Ophthalmol. 2012 Jul;250(7):1089-95. doi: 10.1007/s00417-011-1910-7. Epub 2012 Jan 13.

PMID:
22240936
18.

Suboptimal therapy controls clinically apparent disease but not subclinical progression of Vogt-Koyanagi-Harada disease.

Kawaguchi T, Horie S, Bouchenaki N, Ohno-Matsui K, Mochizuki M, Herbort CP.

Int Ophthalmol. 2010 Feb;30(1):41-50. doi: 10.1007/s10792-008-9288-1. Epub 2009 Jan 17.

PMID:
19151926
19.

Prognostic factors in Vogt-Koyanagi-Harada disease.

Al-Kharashi AS, Aldibhi H, Al-Fraykh H, Kangave D, Abu El-Asrar AM.

Int Ophthalmol. 2007 Apr-Jun;27(2-3):201-10. Epub 2007 Apr 14.

PMID:
17435968
20.

Effects of the duration of initial oral corticosteroid treatment on the recurrence of inflammation in Vogt-Koyanagi-Harada disease.

Lai TY, Chan RP, Chan CK, Lam DS.

Eye (Lond). 2009 Mar;23(3):543-8. doi: 10.1038/eye.2008.89. Epub 2008 Mar 28.

PMID:
18369377

Supplemental Content

Support Center